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Background: Well differentiated liposarcoma (WDLPS) can be difficult to distinguish from lipoma.
Currently, this distinction is made by testing forMDM2 amplification, which requires a biopsy. The aim
of this study was to develop a noninvasive method to predictMDM2 amplification status using radiomics
features derived from MRI.
Methods: Patients with an MDM2-negative lipoma or MDM2-positive WDLPS and a pretreatment
T1-weighted MRI scan who were referred to Erasmus MC between 2009 and 2018 were included.
When available, other MRI sequences were included in the radiomics analysis. Features describing
intensity, shape and texture were extracted from the tumour region. Classification was performed using
various machine learning approaches. Evaluation was performed through a 100 times random-split
cross-validation. The performance of the models was compared with the performance of three expert
radiologists.
Results: The data set included 116 tumours (58 patients with lipoma, 58 with WDLPS) and originated
from 41 different MRI scanners, resulting in wide heterogeneity in imaging hardware and acquisition
protocols. The radiomics model based on T1 imaging features alone resulted in a mean area under the
curve (AUC) of 0⋅83, sensitivity of 0⋅68 and specificity of 0⋅84. Adding the T2-weighted imaging features
in an explorative analysis improved the model to a mean AUC of 0⋅89, sensitivity of 0⋅74 and specificity of
0⋅88. The three radiologists scored an AUC of 0⋅74 and 0⋅72 and 0⋅61 respectively; a sensitivity of 0⋅74,
0⋅91 and 0⋅64; and a specificity of 0⋅55, 0⋅36 and 0⋅59.
Conclusion: Radiomics is a promising, non-invasive method for differentiating between WDLPS and
lipoma, outperforming the scores of the radiologists. Further optimization and validation is needed before
introduction into clinical practice.
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Introduction
Lipomatous tumours are the most commonly observed
soft tissue tumours, mostly owing to the high incidence of
benign lipomas. Also within the malignant spectrum of soft
tissue tumours (soft tissue sarcomas), liposarcoma is among
the most frequently observed subtype1. Well differentiated
liposarcoma (WDLPS) represents the largest subgroup of
liposarcomas; these low-grade, locally aggressive tumours
are characterized by amplification of theMDM2 gene1. In
rare cases, WDLPS can progress into a more aggressive
subtype: dedifferentiated liposarcoma (DDLPS), which has
a poorer prognosis1.
Several differences between lipoma andWDLPS onMRI
have been described in the literature: size, location, tumour
depth and intratumour heterogeneity. However, as there
can be considerable overlap between these features, distin-
guishing between the two tumour types remains difficult,
even for trained radiologists2–6. As the differences between
lipoma/WDLPS and DDLPS are more obvious, this dis-
tinction can accurately be made solely by eye5,7–10.
An accurate diagnosis is needed to provide patients
with the correct treatment and follow-up. Whereas lipo-
mas do not necessarily need to be excised, patients with
WDLPS are generally considered candidates for surgery11.
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Currently, the standard way to differentiate lipoma from
WDLPS is through a biopsy, which is tested for MDM2
amplification using fluorescence in situ hybridization
(FISH). Amplification of the MDM2 gene is present in
WDLPS, but absent in lipoma1,12,13. Taking a biopsy is
an invasive and painful procedure for the patient, and is
associated with risks, depending on tumour location, and
potential sampling error.
The field of radiomics is based on the hypothesis that
there is a relationship between medical imaging features
and the underlying biological information, such as genetic
aberrations14. Radiomics approaches have already been
used in soft tissue sarcomas to predict other outcomes,
such as differentiating between benign and malignant
soft tissue tumours in general (not specifically lipomatous
tumours)15, between intermediate- and high-grade soft tis-
sue sarcomas16, and predicting the risk of lung metastases
from soft tissue sarcoma of the extremities17. Based on
these results, it was hypothesized that radiomics might also
be able to differentiate WDLPS from lipoma.
The aim of this study was to develop amodel that predicts
MDM2 amplification status using a radiomics approach,
thereby differentiating WDLPS from lipoma. MRI scans
obtained during routine diagnostic evaluation were used.
Additionally, the performance of this model was compared
with that of three trained radiologists reading the images.
Finally, patients with DDLPS were included and classified
by the radiologists to confirm that these tumours have
distinct imaging features and can be identified without the
help of additional models or tests.
Methods
Patients with a pathologically confirmed diagnosis of
lipoma, WDLPS or DDLPS, a known MDM2 amplifica-
tion status tested by FISH, and with at least a T1-weighted
MRI sequence available before treatment (if applica-
ble) were included. All patients were either referred
to/discussed at, or diagnosed/treated at the Erasmus MC
Cancer Institute, Rotterdam, the Netherlands, between
December 2009 and August 2018. As a result, some of
the MRI scans were made in the referring hospitals. The
study was reviewed and approved by the local medical
ethics review committee (MEC-2016-339), and performed
in accordance with national and international legislation.
Need for informed consent was waived owing to the
retrospective and anonymized nature of the study.
To explore the potential predictive value of differ-
ent MRI sequences, several additional sequences were
included, when available. Based on their use in clini-
cal practice, the sequences were grouped into: plain T1
(T1); T1 with fat saturation (T1-FS) including T1 inver-
sion recovery (IR) approaches (T1-IR; a combination of
Spectral Presaturation with Inversion Recovery (SPIR),
Short-TI Inversion Recovery (STIR), Spectral Attenuated
Inversion Recovery (SPAIR) and Turbo Inversion Recov-
ery Magnitude (TIRM)); T1 with gadolinium contrast
(T1-GD); T1 with fat saturation and gadolinium contrast
(T1-FS-GD) including T1-IR with GD; T2 imaging (T2)
including T2-Fast Field Echo (T2FFE) and T2*; and
T2-FS including T2-IR.
Segmentation
The lipoma and WDLPS lesions were segmented semi-
automatically on the T1 images to indicate the regions
of interest (ROIs)18. All images were segmented inde-
pendently by either a medical masters student or a PhD
candidate with an MD degree. Both were blinded to the
type of lipomatous tumour. To validate segmentation
accuracy, a sample set was verified by a musculoskeletal
radiologist, specialized in soft tissue sarcomas. Median
tumour size, defined as the maximum diameter in centime-
tres, and tumour volume, with corresponding i.q.r. values,
were extracted from the segmentations. The DDLPS
images were used only for visual classification by the
radiologists, and therefore not segmented.
To transfer the segmentations to the other sequences,
all sequences were spatially aligned to the T1 sequence
using automated image registration (elastix software19),
thereby compensating for patient movement between
scans. Quality assurance was done by visual inspection.
Radiomics feature extraction
Quantitative imaging features related to intensity, shape
and texture were extracted from the ROIs using PyRa-
diomics software20,21. More details can be found in
Appendix S1 (supporting information). The shape features
quantified were morphological properties such as volume
and similarity to a circle. Intensity features were quantified
using first-order statistics such as the mean and standard
deviation. Texture features quantified more complex prop-
erties, such as the presence of heterogeneity and speckle
patterns. When a scan type was missing for a patient, the
feature values for the missing image type were imputed.
Additional features
Several additional features were selected based on the avail-
able literature and clinical relevance, including patient
characteristics (age, sex and tumour location (extremity,
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Fig. 1 Schematic overview of the radiomics approach
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Inputs to the algorithm are T1- and T2-weighted magnetic resonance images of well differentiated liposarcoma (WDLPS) and lipoma (1). Processing
steps include segmentation of the tumour on the T1 image (2), registration of the T1 to the T2 image to transform this segmentation to the T2 image
(3), feature extraction from both the T1 and T2 images (4) and the creation of a decision model from the features (5), using an ensemble of the best 50
workflows from 100 000 candidate workflows; workflows are different combinations of the different processing and analysis steps (for example the classifier
used).
trunk, head and neck or pelvis)) and manually scored fea-
tures (tumour depth (superficial or deep), unilobular or
multilobular tumour, atypical appearance on T1 image
(yes or no)). These are referred to as patient and manu-
ally scored features respectively. Tumours were considered
superficial when entirely located above the fascia, or as
deep-seated when located beneath the fascia, or with inva-
sion of the fascia.
Decision model creation
To create a decision model from the features, the Work-
flow for Optimal Radiomics Classification (WORC)
toolbox22 was used. A schematic overview of the radiomics
methodology is shown in Fig. 1. In WORC, decision
model creation is divided into several steps. These steps
include, for example, selection of features that offer the
highest predictive value and machine learning to discover
the patterns in these features that distinguish between
WDLPS and lipoma. For each of these steps, numerous
algorithms have been proposed in the literature. WORC
performs an exhaustive search amongst these algorithms,
in a fully automated way, and establishes the combination
of algorithms that maximizes the prediction accuracy. As
the single best solution may be a coincidental finding, the
50 best performing solutions were combined into a single
model, with the purpose of creating a more robust model
and boosting performance. More details can be found in
Appendix S2 (supporting information).
Experimental set-up
To assess the predictive value of the T1 imaging features,
and the additional patient and manually scored features,
five models were trained and tested based on: imaging
features only (model 1); patient features only (model 2);
manually scored features only (model 3); a combination of
imaging features and manually scored features (model 4);
and volume only (model 5). The fifth model was included
because WDLPS is generally larger than lipoma3. Addi-
tionally, to investigate the potential of the features inde-
pendent of volume, these five models were evaluated on
a volume-matched cohort, that is a subset of the data
in which the distribution of tumour volume was similar
among WDLPS and lipoma. These models were trained
on the full data set, but tested only on patients from the
volume-matched cohort.
Next, the potential value of other MRI sequences was
explored by training and testing multiple imaging-based
radiomics models using combinations of the various MRI
sequences. When a model showed more potential than
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 1800–1809
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the T1 imaging-only model, it was evaluated on the
volume-matched cohort as well.
Evaluation
Model evaluation was performed through cross-validation.
The data were randomly split for 100 iterations, using 80
per cent for training and 20 per cent for testing. In each
iteration, automatic workflow optimization was performed
on the training set in an internal ten times random split
cross-validation (Fig. S1, supporting information). Thus,
the models were optimized solely on the training set; the
test set was used only for evaluation of the final model. All
splitting was done in a stratifiedmanner to keep the balance
between WDLPS and lipoma similar in all data sets.
Performance was evaluated using the area under the
curve (AUC) of the receiver operating characteristic (ROC)
curve, accuracy, sensitivity, specificity, negative predictive
value and positive predictive value, averaged over the
100 cross-validation iterations. Positive MDM2 amplifi-
cation status (WDLPS) was defined as the positive class.
Ninety-five per cent confidence intervals for the mean per-
formance measures were constructed using the corrected
resampled t test based on all 100 cross-validation itera-
tions, thereby taking into account that the samples in the
cross-validation splits were not statistically independent23.
Model insights
Insight into the model was gained by ranking the patients
from typical to atypical for both lipoma and WDLPS,
based on the consistency of the model predictions. This
was determined by the number of times (percentage) that
a patient was classified correctly when included in the
test set. Typical examples were patients who were always
classified correctly; and atypical vice versa. In addition, to
identify the individual imaging features included in the
radiomics model and to assess their respective contribution
to the model, univariable statistical testing of the imaging
features was undertaken using the Mann–Whitney U test.
P values were corrected for multiple testing using the
Bonferroni correction.
Classification by radiologists
Three radiologists with expertise in soft tissue tumours
classified the lipomatous tumours; radiologists 1, 2 and 3
had 3, 10 and 5 years of experience respectively. First, the
radiologists had to classify the tumours as either DDLPS
or WDLPS/lipoma (non-DDLPS), to confirm that
DDLPS can be recognized visually. Regardless of whether
a tumour was classified as DDLPS or not, the tumours
subsequently had to be classified as MDM2-negative
(lipoma) or MDM2-positive (WDLPS/DDLPS). The
classification was done using a ten-point scale to indicate
the certainty of the radiologists. The radiologists had
access to all sequences that were available for each patient,
as well as the age and sex.
Results
In total, 138 tumours were included: 58 patients had
an MDM2-negative lipoma, 58 had an MDM2-positive
WDLPS and 22 had an MDM2-positive DDLPS. Most
patients were men (60⋅1 per cent) and had a deep-seated
tumour located in a leg. Median WDLPS size was 20⋅4 cm
andmedian volumewas 36⋅3 cl, comparedwith 12⋅3 cm and
12⋅9 cl for lipoma (Table 1). Most of the patients underwent
surgery: 32 with a lipoma, 50 with a WDLPS and 19 of
those with a DDLPS. The eight patients with a WDLPS
who did not have surgery were treated conservatively with
an active surveillance approach, whereas the three with
a DDLPS who did not have surgery had an inoperable
tumour.
The 116 lipoma andWDLPS scans came from 41 differ-
entMRI scanners; there was wide heterogeneity in imaging
Table 1 Characteristics of the patients with lipomatous tumours
No. of patients*(n =138)
Age (years)† 64 (54–71)
Sex ratio (M :F) 83 : 55
Diagnosis
Lipoma 58 (42⋅0)
WDLPS 58 (42⋅0)
DDLPS 22 (15⋅9)
Tumour location
Upper extremity 14 (10⋅1)
Lower extremity 71 (51⋅4)
Trunk 37 (26⋅8)
Head and neck 6 (4⋅3)
Retroperitoneum and pelvis 6 (4⋅3)
Paratesticular 4 (2⋅9)
Tumour depth
Superficial 20 (14⋅5)
Deep 118 (85⋅5)
Tumour size (cm)†
Lipoma 12⋅3 (9⋅3–15⋅5)
WDLPS 20⋅4 (15⋅9–26⋅3)
Tumour volume (cl)†
Lipoma 12⋅9 (4⋅6–25⋅0)
WDLPS 36⋅3 (22⋅9–85⋅5)
*With percentages in parentheses unless indicated otherwise; †values are
median (i.q.r.). WDLPS, well differentiated liposarcoma; DDLPS, dedif-
ferentiated liposarcoma.
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hardware and acquisition protocols used, reflected in dif-
ferences in magnetic field strength (1⋅5T, 98 scans; 1T,
10 scans; 3T, 8 scans), manufacturer (Siemens, Munich,
Germany, 45 scans; Philips, Amsterdam, the Netherlands,
45 scans; GE, Chicago, Illinois, USA, 26 scans), scanner
model (19 different ones), slice thickness, repetition time
and echo time. Additional sequences besides T1 were avail-
able in subsets of patients: T1-FS in 55 patients (47⋅4 per
cent), T1-GD in 42 patients (36⋅2 per cent), T1-FS-GD
in 80 patients (69⋅0 per cent), T2 in 76 patients (65⋅5 per
cent) and T2-FS in 92 patients (79⋅3 per cent) (Table S1,
supporting information).
Evaluation of radiomics models based on T1
imaging and additional features
The performances of models 1–5 are shown in Fig. 2 and
Table S2 (supporting information). Model 1, based on the
T1 imaging features, resulted in an AUCof 0⋅83, sensitivity
of 0⋅68 and specificity of 0⋅84. Model 2, based on patient
features, had a lower AUC (0⋅75), higher sensitivity (0⋅77),
but lower specificity (0⋅59). Similarly, model 3, based on
manually scored features, also had a lower AUC (0⋅72),
higher sensitivity (0⋅76) and lower specificity (0⋅57). Model
4, combining the imaging and manually scored features,
performed worse than model 1, implying that imaging
features are sufficient as input. Finally, model 5, based on
volume alone, performed similarly tomodel 1 with an AUC
of 0⋅83, sensitivity of 0⋅67 and specificity of 0⋅84. Although
the performance metrics were similar for models 1 and 5,
the ROC curves in Fig. 2 show some differences. The ROC
curve for the volume model (Fig. 2e) has some sharp bends,
while that for the T1 imaging model is smoother (Fig. 2a).
Evaluation of the radiomics models with additional
MRI sequences
Most models with an additional MRI sequence had a
similar performance to the T1 imaging model (Table S3,
supporting information). However, the model combining
the T1 and T2 imaging features showed a clear improve-
ment in performance, with an AUC of 0⋅89, sensitivity of
0⋅74 and specificity of 0⋅88. The distribution of patient
characteristics and the distribution of WDLPS and lipoma
were similar across patients who had a T2 scan, indi-
cating that the added value is within the T2 imaging
features and not a result of incidental correlation with
these characteristics, for example owing to selection bias.
Evaluation of models on volume-matched cohort
Model 5, based on volume alone, illustrated that volume
is indeed a strong predictive factor. The 17 tumours with
a volume above 70 cl were all WDLPS, whereas the 21
tumours with a volume below 7 cl were all lipoma. In
the volume-matched cohort, consisting of the other 78
tumours with a volume between 7 and 70 cl, the volume
distributions for WDLPS and lipoma were more similar.
As only the T2 scans provided additional value over the
T1 imaging features, the T1+T2 imaging model was
evaluated for the volume-matched cohort as well.
The performance of both imaging-based models (T1 and
T1+T2) was worse on the volume-matched cohort (T1:
AUC 0⋅69; T1+T2: AUC 0⋅81) (Table 2) than on the entire
cohort (AUC 0⋅83 and 0⋅89 respectively) (Table S3, sup-
porting information). The models based on the patient
and manually scored features performed similarly to the
models tested on the full cohort. The model based on
volume alone still performed above chance (mean AUC
0⋅64), but considerably worse than on the entire data set.
In this volume-matched data set, both the T1 imaging
model (AUC 0⋅69, sensitivity 0⋅60, specificity 0⋅74) and
the T1+T2 imaging model (AUC 0⋅81, sensitivity 0⋅66,
specificity 0⋅84) performed considerably better than vol-
ume alone (Table 2). This showed that these models were
not based solely on volume, and that other features pro-
vided additional predictive value over volume.
Model insights
Of the 116 lipomatous tumours, 69 (26 WDLPS, 43
lipoma) were always classified correctly by model 1 in all
100 cross-validation iterations. In contrast, 13 tumours
(9 WDLPS, 4 lipoma) were always classified incorrectly.
Fig. 3 shows four MRI slices of such typical and atypical
examples of lipoma and WDLPS. The lesions that were
always classified incorrectly were checked for possible sam-
pling error of the biopsy. The MDM2 amplification status
of eight of the 13 tumours always classified incorrectly was
already determined on the resection specimen (6WDLPS,
2 lipoma). For the other five patients, in whom it was tested
on the biopsy (3 WDLPS, 2 lipoma), pathological exami-
nation of the resection specimen confirmed the diagnosis,
except for one patient with a lipoma who did not undergo
surgery. In the other patient with a lipoma, the resection
specimen again tested negative for MDM2 amplification.
The threeWDLPS resection specimens were not retested.
Analysis of feature importance was done for the
volume-matched cohort, as the results on the full data
set were dominated by volume-related measures. In total,
16 individual features were found to be significant after
Bonferroni correction on the volume-matched cohort
(Fig. S2, supporting information). These included 11
shape features (including several volume-related statistics),
four texture features and one intensity feature.
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 1800–1809
on behalf of BJS Society Ltd.
Radiomics in lipomatous tumours 1805
Fig. 2 Receiver operating characteristic (ROC) curves for the radiomics models based on the T1-weighted MRI sequence
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Radiomics models compared with radiologists
On the entire cohort, the AUCs of all three radiologists
(0⋅74, 0⋅72 and 0⋅61 for radiologist 1, 2 and 3 respectively)
(Table S4, supporting information) were below the lower
limit of the 95 per cent c.i. of the T1 imaging model (0⋅75
to 0⋅90) (Fig. 2 and Table S2, supporting information), as
well as of the 95 per cent c.i. of the T1+T2 imaging model
(0⋅83 to 0⋅95) (Table S3, supporting information). The
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Table 2 Performance of radiomics models trained on the full cohort, but evaluated in the volume-matched cohort
T1 imaging features only T1+T2 imaging features Patient features only Manually scored features only Volume only
AUC 0⋅69 (0⋅58, 0⋅80) 0⋅81 (0⋅72, 0⋅90) 0⋅74 (0⋅64, 0⋅84) 0⋅67 (0⋅56, 0⋅77) 0⋅64 (0⋅53, 0⋅74)
Accuracy 0⋅67 (0⋅57, 0⋅76) 0⋅75 (0⋅66, 0⋅83) 0⋅66 (0⋅56, 0⋅75) 0⋅60 (0⋅51, 0⋅69) 0⋅66 (0⋅57, 0⋅74)
Sensitivity 0⋅60 (0⋅45, 0⋅75) 0⋅66 (0⋅52, 0⋅79) 0⋅69 (0⋅55, 0⋅83) 0⋅70 (0⋅53, 0⋅87) 0⋅50 (0⋅36, 0⋅64)
Specificity 0⋅74 (0⋅60, 0⋅87) 0⋅84 (0⋅71, 0⋅96) 0⋅62 (0⋅48, 0⋅76) 0⋅51 (0⋅36, 0⋅65) 0⋅82 (0⋅71, 0⋅92)
NPV 0⋅66 (0⋅54, 0⋅77) 0⋅72 (0⋅60, 0⋅83) 0⋅68 (0⋅56, 0⋅79) 0⋅65 (0⋅49, 0⋅80) 0⋅62 (0⋅53, 0⋅71)
PPV 0⋅72 (0⋅58, 0⋅85) 0⋅81 (0⋅69, 0⋅93) 0⋅65 (0⋅54, 0⋅76) 0⋅59 (0⋅49, 0⋅69) 0⋅74 (0⋅61, 0⋅87)
Values are mean (95 per cent c.i.) over the cross-validation iterations. AUC, area under the curve; NPV, negative predictive value; PPV, positive predictive
value.
Fig. 3 Examples of typical and atypical lipomas and well differentiated liposarcomas
a  Typical lipoma b  Atypical lipoma
c  Atypical WDLPS d  Typical WDLPS
aTypical lipoma, b atypical lipoma, c atypical well differentiated liposarcoma (WDLPS) and d typicalWDLPS. The typical examples are from two patients
always classified correctly by the T1 imaging model; the atypical examples are from two patients always classified incorrectly by the T1 imaging model.
radiologists achieved sensitivity values similar to (0⋅64 and
0⋅74) or higher (0⋅91) than those of the radiomics models
(T1: 0⋅68; T1+T2: 0⋅74), but their specificity was much
lower (radiomics: 0⋅84 and 0⋅88 respectively; radiologists
1–3: 0⋅55, 0⋅36 and 0⋅59 respectively). The Cohen’s κ value
was 0⋅24, 0⋅04 and 0⋅40 for all pairs of radiologists, with a
mean of 0⋅23, indicating poor interobserver agreement.
On the volume-matched cohort, the radiologists had
a performance (AUC 0⋅68, 0⋅74 and 0⋅55) (Table S4,
supporting information) more similar to that of the T1
imaging model (AUC 0⋅69) (Table 2). On average, the T1
imaging model still performed better in terms of speci-
ficity (radiomics: 0⋅74; radiologists 1–3: 0⋅58, 0⋅37 and
0⋅50), whereas the radiologists again performed better on
sensitivity (radiomics: 0⋅60; radiologists 1–3: 0⋅65, 0⋅88 and
0⋅60). However, the T1+T2 imaging model performed
much better (AUC 0⋅81, sensitivity 0⋅66, specificity 0⋅84)
than both the T1 imaging model and the radiologists. On
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this cohort, the Cohen’s κ values were 0⋅18, –0⋅04 and 0⋅34
for all pairs of radiologists, with a mean of 0⋅16, again indi-
cating poor interobserver agreement.
Distinction between dedifferentiated liposarcoma
and well differentiated liposarcoma/lipoma
Besides classifying lipoma and WDLPS, the radiologists
also classified the scans from 22 patients with DDLPS
to evaluate whether DDLPS can indeed be identified
by imaging only, without the help of additional models.
Radiologists 1–3 had an AUC of 0⋅97, 0⋅91 and 0⋅90
respectively; a sensitivity of 0⋅95, 0⋅95 and 0⋅91; and a
specificity of 0⋅95, 0⋅56 and 0⋅89 in distinguishing DDLPS
from non-DDLPS (WDLPS/lipoma) (Table S4, supporting
information).
Discussion
This study shows that there is a relationship between quan-
titative MRI features andMDM2 amplification status, and
that radiomics is a promising non-invasive method for
differentiating lipoma from WDLPS. Although the radi-
ologists were able to distinguish between DDLPS and
non-DDLPS, they were outperformed by the T1 and
T1+T2 imaging models in differentiating WDLPS from
lipoma. Moreover, the agreement between radiologists was
very poor, whereas the radiomics-based predictions were
objective and reproducible (given a tumour segmentation).
Remarkably, the model trained on volume alone had
a similar performance to the T1 imaging model, which
included many additional features. However, in the
volume-matched data set, the T1 imaging model per-
formed considerably better than the volume-only model,
indicating that other features do provide additional predic-
tive value. It is already known that WDLPS is on average
larger than lipoma3, and the relationship with volume (or
size) in our data set was also strong; the database did not
contain lipoma larger than 70 cl or WDLPS smaller than
7 cl although these do exist24,25. However, all WDLPS
lesions start as small tumours and grow over time, so the
measured tumour volume depends on the moment of pre-
sentation, and a small or intermediate tumour volume is
therefore not a reliable biomarker. Future research should
include expansion of the data set to make the volume
distributions more representative (including lipoma larger
than 70 cl and WDLPS smaller than 7 cl), thereby making
the radiomics model less volume-dependent.
The models trained solely on either the patient or
manually scored features performed slightly worse than
the model trained on the T1 imaging features only. As
the combined model did not outperform the T1 imaging
model, the manually scored features did not add much
in the search for the best radiomics model. Additionally,
the manually scored features may be observer-dependent,
and thus prone to subjectivity. Although patient features
(age, sex and tumour location) are objective, the distri-
bution in the present data set may not be representative
of clinical practice. For example, none of the patients
with WDLPS were younger than 35 years, there were no
lipomas among patients older than 82 years, no lipomas in
the head and neck region, and no WDLPS in the pelvis
or shoulder/trunk; all these might occur in daily clinical
practice. Therefore, the imaging-only models have more
potential as an objective tool in clinical practice.
The results of present study are similar to those of
Thornhill and colleagues26, who used a comparable
approach and showed that lipomas can be distinguished
from liposarcomas by texture and shape analysis. Strong
points of the present study include the larger sample
size (116 versus 44 in Thornhill et al.). Thornhill and
co-workers also included other liposarcoma subtypes in
their model, such as DDLPS and myxoid liposarcoma (8
of 20 included liposarcomas). These other liposarcoma
subtypes have distinct radiological features5,10, which in
general can be easily discriminated from lipomas by expe-
rienced radiologists. By solely including the two tumour
types that are the most difficult to distinguish (WDLPS
and lipoma) in the radiomics model, the present data set is
more challenging and more clinically relevant. In contrast
to the cases described by Thornhill et al., the diagnosis
of all patients in the present data set was confirmed by
verifying the MDM2 amplification status using FISH,
the current standard for diagnosing and differentiating
between lipoma andWDLPS1,12,13. The present radiomics
model only requires routineMRI scans (T1, and optionally
T2) without contrast injection; the other sequences did
not add any predictive value to the model. As almost all
standard MRI protocols include a T1 and T2 sequence,
the present radiomics method is generalizable, feasible and
applicable for use in daily practice. Finally, these radiomics
models were developed and evaluated on a heterogeneous
data set, thereby increasing the chance that the reported
performance can be reproduced in a routine clinical setting
when using other MRI scanners.
Advantages of using a radiomics approach over patho-
logical assessment to differentiate between lipoma and
WDLPS include sparing patients an invasive and painful
biopsy, and saving the substantial costs of a radiologist per-
forming the imaging-guided biopsy and of the pathologist
assessing it, including the costs of molecular testing by
FISH. Radiomics makes use of MRI images obtained dur-
ing routine diagnostic evaluation and patients do not need
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to undergo any additional procedure. When radiomics
becomes a widely available tool, patients withWDLPS can
be identified and referred to a soft tissue sarcoma expert
centre at an earlier stage, with potential beneficial effects
on further diagnostics, treatment and follow-up.
Several limitations of this study should be noted, besides
the volume bias already mentioned. First, segmentation of
ROIs of the tumours was done manually, which inherently
leads to both interobserver and intraobserver variability, as
has been quantified for other cancer types27–29. Variabil-
ity in segmenting the ROIs might lead to variability in the
extracted imaging features and subsequently influence the
classification of tumours. Additionally, manual segmenta-
tion is rather time-consuming. This could be addressed by
use of automated segmentation tools that might be avail-
able in the future. Second, variation in imaging protocols
might have influenced the imaging statistics. No restric-
tions were put on the T1 MRI sequences regarding field
strength, slice thickness, or other MRI acquisition set-
tings, as selecting a single protocol is an unrealistic reflec-
tion of daily clinical practice and would have made the
results non-generalizable. Instead, this study shows that the
present radiomics approach is robust to these variations by
both training and testing themodel on heterogeneous data.
Third, the model is based on retrospectively collected data,
which might have led to selection and information bias.
This potential selection bias might have occurred partic-
ularly in the lipoma subgroup, as usually only large and
atypical lipomas are referred to a sarcoma centre. However,
this probably made the data set even more challenging and
relevant, as these can be seen as the complex cases. Addi-
tion of the ‘small and typical’ lipomas would have made the
classification easier, and radiomics is not needed to make
the distinction for such lipomas.
The present radiomics model could serve as a
non-invasive, quick and low-cost alternative to a biopsy.
Although the model needs optimization to match the
accuracy of a biopsy, there could be a certain patient group
for whom the model may already be useful. For example,
patients at high risk of complications of biopsy, or those
in whom the radiomics model can predict the MDM2
amplification status with a high degree of certainty, could
already be treated according to the prediction of the
radiomics model. Although further research is required
to identify which patients could benefit most from the
present model, initial misclassification of a WDLPS as a
lipoma would not harm the patient, considering that active
surveillance seems a safe option in patients without (inval-
idating) symptoms and/or tumour growth, at least in the
short term30. In addition, the performance of the radiomics
model improved substantially whenT2 images were added.
However, only 65⋅5 per cent of the patients had a T2 scan
available, so for a follow-up study it is proposed to use
MRI with at least both T1 and T2 sequences.
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